According to unsealed company files, drug company Eli Lilly had employees write medical journal studies about the antipsychotic Zyprexa, and then asked doctors to put their names on the articles, a practice called “ghostwriting.”

Lilly employees also compiled a guide to hiring scientists to write favorable articles and submitted rejected articles to other outlets.

Lilly sought to make Zyprexa “the number one selling psychotropic in history.” The memo was among more than 10,000 pages of internal documents unsealed last month in lawsuits by insurers and pension funds seeking to recoup money spent on the drug. They allege Lilly exaggerated Zyprexa’s effectiveness.